Global Isoniazid APIs Market Growth 2025-2031

The global Isoniazid APIs market size is predicted to grow from US$ 23.8 million in 2025 to US$ 37.5 million in 2031; it is expected to grow at a CAGR of 7.9% from 2025 to 2031.

Isoniazid (INH) is an important active pharmaceutical ingredient (API) used primarily for the treatment and prevention of tuberculosis (TB). It is one of the first-line anti-tuberculosis drugs and is often used in combination with other TB medications like rifampicin, pyrazinamide, and ethambutol.

United States market for Isoniazid APIs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Isoniazid APIs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Isoniazid APIs is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Isoniazid APIs players cover Amsal Chem Private Limited, China Res Double-Crane Pharmaceutical, Tianjin Handewei Pharmaceutical Co.,Ltd, Calyx Chemicals and Pharmaceuticals Ltd., Anuh Pharma Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Isoniazid APIs Industry Forecast” looks at past sales and reviews total world Isoniazid APIs sales in 2024, providing a comprehensive analysis by region and market sector of projected Isoniazid APIs sales for 2025 through 2031. With Isoniazid APIs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Isoniazid APIs industry.

This Insight Report provides a comprehensive analysis of the global Isoniazid APIs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Isoniazid APIs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Isoniazid APIs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Isoniazid APIs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Isoniazid APIs.

This report presents a comprehensive overview, market shares, and growth opportunities of Isoniazid APIs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Purity: Min 98%
Purity: Min 99%

Segmentation by Application:
Tablets
Capsules

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Amsal Chem Private Limited
China Res Double-Crane Pharmaceutical
Tianjin Handewei Pharmaceutical Co.,Ltd
Calyx Chemicals and Pharmaceuticals Ltd.
Anuh Pharma Ltd.
YUKI GOSEI KOGYO CO.,LTD
Shanghai New Asia Pharmaceutical Co. Ltd.
Suzhou Fifth Pharmaceutical Factory Co.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Isoniazid APIs market?

What factors are driving Isoniazid APIs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Isoniazid APIs market opportunities vary by end market size?

How does Isoniazid APIs break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.